A B ST R A CT The receptor for Factor VIII/von Wil- lebrand factor (F. VIIIVwF) is not readily available on circulating platelets. We have found that the stimulation of platelets with traces of thrombin at concentrations that are generated physiologically (0.008 U-0.05 U/ml) induced concentration-dependent binding of '251-labeled F. VIIIvwF in a steady-state system. The binding induced by thrombin was specific because it was inhibited by a 100-fold molar excess of unlabeled F. VIIIVWF factor, by rabbit monospecific antibody against Factor VIII, and was not inhibited by an excess of fibrinogen or fibronectin. Binding induced by thrombin required metabolically active platelets, in contrast to a system with ristocetin that also prompted binding to glutaraldehyde-treated platelets. The thrombin effects on binding of 125I-F. VIIIvwF was not observed when platelets were washed with EDTA-containing buffers; EDTA and EGTA both inhibited thrombin-induced binding. Platelet membrane glycoproteins were required because enzymatic stripping of them from the platelet surface with chymotrypsin reduced binding 2.5-5.0-fold. Prostacyclin, in the concentration range of 1 to 50 nM, had two distinct effects on the receptor for F. VIIIvwF: (a) it prevented exposure of this receptor when added 10 min before thrombin, and (b) it reversed the binding of 125I-F. VIIIVwF to the platelet receptor when added 30 min after thrombin and the ligand, i.e., when binding was at equilibrium. The dual effect of prostacyclin on the receptor for F. VIIIVwF was reproduced by dibutyryl cyclic AMP.
INTRODUCTION
Formation of a platelet plug at the site of vascular injury is of fundamental importance in normal hemostasis. Plasma Factor VIII/von Willebrand factor (F. VIIIVwF)' is required for the interaction of platelets with an injured vessel wall (1) . Individuals lacking this glycoprotein demonstrate a bleeding tendency, owing to their inability to form a functionally competent hemostatic plug (2) . However, the exact in vivo mechanism(s) of the interaction between platelets and F.
VIIIVwF is not known.
Under normal physiologic conditions, plasma F. VIIIVwF is loosely associated with platelets. After their removal from the plasma atmosphere, such platelets do not adhere to the subendothelial space in a rabbit aorta, and they do not aggregate in the presence of the antibiotic ristocetin (3, 4) . Aggregation or agglutination of platelets in the presence of ristocetin requires F. VIIIVWF, and this factor becomes tightly "associated" with human platelets (5) (6) (7) (8) . It has been recently reported that ristocetin induces binding of 31,000 molecules of F. VIIIVwF (M, 1.1 X 106) per one platelet (9) . This ristocetin-induced binding of F. VIIIVWF is of relatively high affinity and demonstrates a functional correlation with platelet aggregation (10) . Whereas ristocetin is a useful laboratory tool to study and diagnose abnormalities in the interaction of von Willebrand factor with human platelets (4), we undertook a search for a physiologic mechanism(s) that can be operative in vivo to induce and regulate the interaction of F. VIIIVwF with human platelets.
Our results indicate that thrombin at concentrations that are generated physiologically (11) (19) .
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Electrophoresis was performed according to the procedure of Weber and Osborn (24) . Samples were reduced in the presence of 1% dithiothreitol at 37°C for 30 min. The percentages of acrylamide used for electrophoresis were either 5 or 7.5%.
Other assays. Protein concentrations in the samples were measured by the method of Lowry (25) . Fibrinogen content of purified F. VIIIVWF was checked with the staphylococcal clumping test which can detect 0.5 ug fibrinogen/ml (26) and by radioimmunoassay detecting at least 10 ng of fibrinogen per milliliter. Immunodiffusion reactions were performed by the double diffusion method of Ouchterlony (27) using the diffusion plates prepared with 1.2% agar in veronal buffer, pH 8.5, I = 0.5.
RESULTS
We have used purified 1251-F. VIIIVWF for quantitative binding studies. F. VIIIVwF isolated from human Factor VIII concentrate by a standard procedure (18) , was purified further by affinity chromatography to assure removal of fibrinogen and fibronectin, which contaminate Factor VIII preparations (28) . Such purified F. VIIIVwF gave a single band on SDS-PAGE under reducing conditions. Electrophoresis of iodinated F. VIIIVwF produced a single peak of radioactivity that was parallel with the protein band (Fig. 1, top panel) . Whereas fibrinogen was present in concentrations of 22 Ag/l mg of preparations of F. VIIIVWF before immunoaffinity chromatography, it was not detected thereafter using immunodiffusion or the staphylococcal clumping test with a limit of detectability 0.5 ,ug fibrinogen/ml (26) . In an even more sensitive radioimmunoassay procedure, the fibrinogen content was <60 ng/l mg of F. VIIIVWF, i.e., <0 Platelets (1 X 108 cells) were treated with thrombin for 3 min and then 125j-F. VIIIVWF (0.8 ug) was added. At specified time intervals, platelets were rapidly centrifuged (8,000 g for 2 min) through an oil mixture to separate platelet-bound ligand from unbound material.
Binding of 125I-F. VIIIVWF to metabolically intact platelets as compared with glutaraldehyde-fixed platelets. In these experiments, we compared the effect of thrombin on binding of F. VIIIVwF to metabolically intact platelets with that of glutaraldehydefixed platelets. Only intact platelets showed responsiveness to thrombin in terms of induction of binding of 125I-F. VIIIVwF (Fig. 4) . In contrast to thrombin, ristocetin induced binding to both metabolically intact platelets and glutaraldehyde-treated platelets. The binding shown in Fig. 4 represents subsaturating conditions because the percentage of total added 1251-F.
VIIIVwF that was bound increased upon addition of increasing concentrations of 1251-F. VIIIVwF Prostacyclin inhibition of binding of 125I-F. VIIIVWF to thrombin-activated platelets. In these experiments, we examined whether prostacyclin inhibits the process of F. VIIIVwF receptor exposure by thrombin and ristocetin. Prostacyclin inhibited, in a concentration-dependent manner, binding of 1251-F. VIIIVwF to human platelets induced by low thrombin concentration (0.01 U/ml) (Fig. 7) . On the other hand, PGI2 was not inhibitory toward binding of 125I-F. VIIIVwF to human platelets treated with ristocetin. Although PGI2 was inhibitory at the concentration range 1-10 nM, the inhibition by 6 keto PGF1,, was not observed at 1 nM and only 24% binding was inhibited at 10 nM. This effect of 6 keto PGF10) represented -2% of the inhibitory potency of PGI2.
The effects of time of addition of PGI2 on inhibition of binding of '25I-F. VIIIVWF to human platelets. To distinguish between the two possible modes of action of prostacyclin on the interaction of F. VIIIVwF with human platelets, i.e., the effect of PGI2 on the process of receptor induction by thrombin, and the effect of PGI2 on the already formed ligand-receptor complex, the following experiments were conducted. PGI2 was added to platelets at different stages of thrombin-platelet and platelet-'25I-F. VIIIVwF interactions.
In the first experiments, PGI2 was added to human platelets 3 min before addition of thrombin, which was followed 8 min later by addition of '25I-F. VIIIVwF. A concentration-dependent inhibition of 1251-F. VIIIVwF binding by PGI2 was observed as shown in Fig. 7 . Addition of PGI2 10 min before thrombin (0.01 U/ml) did not change the inhibitory effect of this prostaglandin. A more striking effect of the prostacyclin action was noted when prostacyclin was added following thrombin and 1251-F. VIIIVwF. Whether PGI2 was added 3, 10, or even 30 min after, the effect was the same, namely inhibition of binding of 1251-F. VIIIVwF by the same range of prostacyclin concentrations.
The effect of PGI2 added to platelets after 1251-F.
VIIIVwF was investigated in more detail by following the time-course of binding (Fig. 8) . When (31, 32) . Therefore, its inhibitory effect on the binding of '251-F. VIIIVwF can be mediated by cAMP, which is generated as a result of PGI2 action. To examine this possibility, we performed a series of experiments in which PGI2 was substituted with dcAMP. We have observed a concentration-dependent inhibition of binding by dcAMP (Fig. 9) 
